The microalgae cell: vegetal factory for the production of biopharmaceuticals and vector for mucosal delivery.

Bioproduction of recombinant proteins (immunotoxins, fusion proteins, thermostable sub-unit vaccines, ...).

Our mission, our innovation

Produce recombinant proteins using our own microalgae multigenic cell lines.
Produce biotherapeutic proteins for applications in oncology, infectiology, vaccinology, differentiating from current eukaryotic expression systems (animal cells, yeasts):
- recombinant immunotoxins and fusion proteins: Ninkarak^® platform.
- thermo-stable vaccines, with vegetal adjuvants: Algavax^® platform.
Develop a microalgae galenic pharmacology by our expertise in controlled cellular fragmentation of microalgae
- nasal, oral, pulmonary, topical delivery, avoiding parenteral injection: Algapharm^® platform.
Scale-up from the laboratory to industry, assembling established technologies and novel proprietary vectoring systems.
Manufacture products in commercial quantities at a reduced cost, respecting the quality requirements of the pharmaceutical industry.
Extend to other ‘hostile’ molecules, eventually to glycoproteins, to monoclonal antibodies.

IASO BIOPRODUCTION, a strategic vision

1. Eukaryotic microalgae

Highly productive, stable, multigenic microalgae cell lines

2. USP bioproduction

Industrial fermentation in accordance with pharmaceutical practices

3. DSP bioproduction

Vectoring of the biodrugs by addressing the proteins in precise cellular compartments

4. Galenic pharmacology

Targeted delivery and controlled release from microalgae cells or fragments

5. Industrial platform

Industrial bioproduction of recombinant proteins, peptides and glycoproteins.

Biopharmaceuticals and microalgae

We use eukaryotic microalgae to produce therapeutic proteins, suitable in formulation for mucosal (nasal, oral, pulmonary) or topical delivery.

A concentrated expertise

Biological engineering

Genetic and biological engineering of eukaryotic microalgae: multigenic, nuclear and chloroplastic expression on different strains. Creating our own cell lines capable of producing proteins in targeted compartment of the cell.

Process engineering

Upstream and downstream process engineering, including production, optimization and process integration, harvesting, fractionation-purification, in accordance with pharmaceutical industry practices and with regulations.

Pharmacological engineering

Pharmacological and galenic engineering in the designing and manufacturing of biodrugs vectored in microalgae cells for oral, mucosal, topical deliveries.

Engineering of industrial systems

Industrial and commercial development through systems engineering, stage-gating methodology, quantitative risk analysis and management.

Science & Technology Council

A Scientific and Technological Council bringing together renowned experts from industry, biotechnology, pharmacology and molecular biology.

Our ambition at the heart of medical innovation

Key figures

8 years

to full commercial application, producing kg of recombinant protein

50 %

the share that biodrugs will occupy in the global pharmacy market by 2030

6 hours

the time it takes for an archetypal microalgae to double its mass by phototrophic growth

10 €

the target cost to produce one gram of protein when vectored in microalgae cells

Contact us

Name

Phone

Email

Message

Thank you, your message has been sent

IASO BIOPRODUCTION SAS
Head office: 3 chemin des Balmes, F-69110 Sainte-Foy-les-Lyon (France)
Establishment (project): SkyeHub Skyepharma, 55 rue du Montmurier, F-38070 Saint-Quentin-Fallavier (suburb of Lyon, France)

IASO BIOPRODUCTION SAS - biopharmaceuticals vectored in microalgae cells: an industrial platform.